Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589744 | 0.86 | FFAR1 (0.51) | FFAR1TAAR1NR4A2HCAR2ALOX5 | |
| SCHEMBL360528 | 0.83 | NR4A2 (0.55) | FFAR1NR4A2HCAR2 | |
| SCHEMBL1625096 | 0.83 | TAAR1 (0.47) | FFAR1TAAR1ALOX5CHRM5CHRM1 | |
| SCHEMBL28648032 | 0.82 | TAAR1 (0.61) | TAAR1HCAR2DAO | |
| SCHEMBL3257843 | 0.81 | PPARA (0.48) | TAAR1HCAR2ALOX5CHRM5CHRM1 | |
| SCHEMBL3248092 | 0.81 | FFAR4 (0.55) | FFAR1HCAR2 | |
| SCHEMBL2185793 | 0.81 | FFAR1 (0.49) | FFAR1TAAR1HCAR2 | |
| SCHEMBL4393843 | 0.81 | FFAR4 (0.49) | FFAR1TAAR1ALOX5CHRM5CHRM1 | |
| SCHEMBL3893736 | 0.81 | ALDH1A1 (0.51) | FFAR1TAAR1NR4A2HCAR2 | |
| SCHEMBL320664 | 0.80 | FFAR4 (0.56) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007372-B1 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-7928106-B2 | 2-[2-(2,5-Difluoro-phenyl)-ethoxymethyl]-3H-pteridin-4-one; 2-2-(3-Fluoro-phenyl)-ethoxymethyl]-3H-pyrimido[4,5-d]pyrimidin-4-one; (5-Oxo-5,6-dihydro-pyrimido[4,5-c]pyridazin-7-ylmethyl)-carbamic acid benzyl ester, useful in treating diseases which are modulated by HM74A agonists e.g. dyslipidemia | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2029601-B1 | PYRIDOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2139895-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-7572801-B2 | Pyridopyrimidinone derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090092580-A1 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090092580-A1 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECHNOLOGIES INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2029601-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008116742-A1 | AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | HOFFMAN-LA ROCHE INC | 2007-11-29 | — | — | US | disclosed |
| WO-2007134986-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007121471-A2 | DIALKYL ETHER DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | GPR119, HCAR1, GPR84 | FFAR1 14/4885TAAR1 42/4885NR4A2 207/4885 |
| US-20090092580-A1 | DIALKYL ETHER DELIVERY AGENTS | LIPA, SLC10A1, ABCB11 | FFAR1 1337/4885TAAR1 3015/4885NR4A2 1464/4885 |
| US-20080234277-A1 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES | CHRM1, CHRM2, CHRM4 | FFAR1 239/4885TAAR1 108/4885NR4A2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.